10 Recruiting B-Cell Non-Hodgkin Lymphoma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceTop Recruiting B-Cell Non-Hodgkin Lymphoma Studies
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
📍 University of Maryland Baltimore — Baltimore, Maryland
View Study & Checklist ➔Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 Northwestern University — Chicago, Illinois
View Study & Checklist ➔B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
📍 Mayo Clinic in Florida — Jacksonville, Florida
View Study & Checklist ➔Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
📍 University of Alabama at Birmingham School of Medicine — Birmingham, Alabama
View Study & Checklist ➔Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
📍 University of Kansas Cancer Center — Westwood, Kansas
View Study & Checklist ➔A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
📍 Research Site — Irvine, California
View Study & Checklist ➔Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
📍 University of California San Francisco - Fresno Center for Medical Education and Research — Clovis, California
View Study & Checklist ➔Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
📍 University of Miami — Miami, Florida
View Study & Checklist ➔Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
📍 Wake Forest University Health Sciences — Winston-Salem, North Carolina
View Study & Checklist ➔A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
View Study & Checklist ➔Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
📍 Research Site — Phoenix, Arizona
View Study & Checklist ➔